Suppr超能文献

依普利酮可抑制盐诱导的肾脏血管内皮生长因子表达。

Eplerenone suppresses salt-induced vascular endothelial growth factor expression in the kidney.

作者信息

Eatman Danita, Layas Mohammed F, Bayorh Mohamed A

机构信息

Department of Pharmacology and Toxicology, Morehouse School of Medicine, Atlanta, Ga., USA.

出版信息

Kidney Blood Press Res. 2010;33(3):167-73. doi: 10.1159/000316700. Epub 2010 Jun 23.

Abstract

BACKGROUND/AIM: It is well accepted that high dietary salt intake accelerates both hypertension and target organ damage. We have previously shown that eplerenone attenuates sustained elevated systolic blood pressure in Dahl salt-sensitive (SS) rats. In the present study, we investigated the role of eplerenone on vascular endothelial growth factor (VEGF) expression because we suspected that eplerenone treatment may trigger a unique mechanism that relies on the downregulation of VEGF.

METHODS

Dahl SS rats were fed a high salt (8% NaCl) diet for 3 weeks and then switched to normal salt (0.3% NaCl) diet with or without treatment with eplerenone (100 mg/kg/day), enalapril (30 mg/kg/day) and their combination for an additional 3 weeks.

RESULTS

In addition to reducing blood pressure, eplerenone inhibited glomeruli sclerosis and suppressed the expression of VEGF and endothelial nitric oxide synthase mRNA as well as protein levels.

CONCLUSIONS

Based on these findings, we suggest that in part, VEGF stimulation of endothelial nitric oxide synthase plays a significant role in the eplerenone-induced reversal of the renal and vascular damage caused by high dietary salt intake.

摘要

背景/目的:高盐饮食会加速高血压和靶器官损伤,这一点已被广泛认可。我们之前已表明依普利酮可减轻 Dahl 盐敏感(SS)大鼠持续升高的收缩压。在本研究中,我们探究了依普利酮对血管内皮生长因子(VEGF)表达的作用,因为我们怀疑依普利酮治疗可能触发一种依赖于 VEGF 下调的独特机制。

方法

给 Dahl SS 大鼠喂食高盐(8%氯化钠)饮食 3 周,然后改为正常盐(0.3%氯化钠)饮食,并分别给予或不给予依普利酮(100 毫克/千克/天)、依那普利(30 毫克/千克/天)及其组合,再持续 3 周。

结果

除降低血压外,依普利酮还抑制肾小球硬化,并抑制 VEGF 和内皮型一氧化氮合酶 mRNA 的表达以及蛋白质水平。

结论

基于这些发现,我们认为,VEGF 对内皮型一氧化氮合酶的刺激在依普利酮诱导的、由高盐饮食引起的肾和血管损伤的逆转中发挥了重要作用。

相似文献

1
Eplerenone suppresses salt-induced vascular endothelial growth factor expression in the kidney.
Kidney Blood Press Res. 2010;33(3):167-73. doi: 10.1159/000316700. Epub 2010 Jun 23.
2
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Am J Physiol Renal Physiol. 2009 Sep;297(3):F802-8. doi: 10.1152/ajprenal.00197.2009. Epub 2009 Jun 17.
3
Mineralocorticoid receptor activation contributes to salt-induced hypertension and renal injury in prepubertal Dahl salt-sensitive rats.
Nephrol Dial Transplant. 2010 Sep;25(9):2879-89. doi: 10.1093/ndt/gfq197. Epub 2010 Apr 20.
5
Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
Clin Exp Hypertens. 2006 Feb;28(2):121-32. doi: 10.1080/10641960500468276.
8
Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway.
Hypertension. 2005 Apr;45(4):538-44. doi: 10.1161/01.HYP.0000157408.43807.5a. Epub 2005 Feb 14.
9
Eplerenone suppresses aldosterone/ salt-induced expression of NOX-4.
J Renin Angiotensin Aldosterone Syst. 2011 Sep;12(3):195-201. doi: 10.1177/1470320310391330. Epub 2011 Feb 3.
10
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
Hypertension. 2006 Jun;47(6):1084-93. doi: 10.1161/01.HYP.0000222003.28517.99. Epub 2006 Apr 24.

引用本文的文献

1
Aldosterone Increases Vascular Permeability in Rat Skin.
Cells. 2022 Aug 30;11(17):2707. doi: 10.3390/cells11172707.
2
Deficiency of renal cortical EGF increases ENaC activity and contributes to salt-sensitive hypertension.
J Am Soc Nephrol. 2013 Jun;24(7):1053-62. doi: 10.1681/ASN.2012080839. Epub 2013 Apr 18.

本文引用的文献

1
The importance of cellular VEGF bioactivity in the development of glomerular disease.
Nephron Exp Nephrol. 2009;113(1):e8-e15. doi: 10.1159/000228078. Epub 2009 Jul 9.
2
Aldosterone and progression of kidney disease.
Ther Adv Cardiovasc Dis. 2009 Apr;3(2):133-43. doi: 10.1177/1753944708100409. Epub 2009 Jan 26.
3
Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies.
Clin J Am Soc Nephrol. 2008 Sep;3(5):1511-25. doi: 10.2215/CJN.04140907. Epub 2008 Jun 11.
4
Aldosterone and the vascular system.
J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):331-5. doi: 10.1016/j.jsbmb.2008.03.005. Epub 2008 Mar 6.
5
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.
Clin J Am Soc Nephrol. 2006 Jul;1(4):761-7. doi: 10.2215/CJN.01381005. Epub 2006 May 17.
6
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker.
Hypertension. 2006 Jun;47(6):1084-93. doi: 10.1161/01.HYP.0000222003.28517.99. Epub 2006 Apr 24.
7
Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study.
J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S90-7. doi: 10.1681/ASN.2005121324.
8
Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
Clin Exp Hypertens. 2006 Feb;28(2):121-32. doi: 10.1080/10641960500468276.
9
Regression of existing glomerulosclerosis by inhibition of aldosterone.
J Am Soc Nephrol. 2005 Nov;16(11):3306-14. doi: 10.1681/ASN.2004090804. Epub 2005 Sep 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验